North America In Vitro Fertilization Market Outlook, 2025-2035
The North America In Vitro Fertilization (IVF) Market is witnessing robust growth, driven by advancements in reproductive technologies, rising infertility rates, and increased societal acceptance of assisted reproductive techniques. Applications span across female and male infertility treatments, genetic disorder screening, embryonic disorders, and surrogacy. The market serves a broad spectrum of end-users, including hospitals, fertility centers, cryobanks, research labs, and pharmacies. Factors such as technological innovation (like vitrification and ICSI), favorable regulatory support, and rising demand from older demographics are propelling the industry's expansion. The region is also benefitting from the presence of leading players and increased investment in fertility research.
Latest Market Dynamics
Key Drivers
- Increasing prevalence of infertility—According to Progyny Inc., there has been a rising incidence of both male and female infertility in North America, driven by delayed childbearing, lifestyle factors, and increasing awareness, boosting demand for IVF services in 2025.
- Advancements in IVF technology—CooperSurgical Inc. has led the integration of innovations such as improved cryopreservation methods and genetic screening (PGD/PGS), enhancing success rates and attracting more patients to IVF treatments.
Key Trends
- Rising uptake of genetic testing—Companies like Thermo Fisher Scientific Inc. are expanding PGD/PGS screening offerings, responding to higher demand for healthy embryos and improved outcomes in IVF cycles.
- Growing adoption of fertility preservation—Vitrolife AB and Cook Medical have noted an increase in frozen egg and embryo banking as more women opt to preserve fertility for social or medical reasons.
Key Opportunities
- Expansion into underserved markets—Boston IVF is setting up new clinics in smaller cities, tapping into growing demand outside major urban centers.
- Integration of AI and automation—Genea Biomedx is investing in AI-powered embryo selection, presenting an opportunity to improve IVF efficiency and outcomes.
Key Challenges
- High treatment costs—Despite technological advances, the overall cost of IVF remains a hurdle for many patients, highlighted by Merck KGaA's efforts to develop cost-effective treatment protocols.
- Regulatory complexities in cross-border treatments—Ferring Pharmaceuticals faces ongoing challenges adapting to varying regulatory standards for donor gametes and embryo procedures between the US, Canada, and Mexico.
Key Restraints
- Ethical and legal concerns—Companies like EMD Serono Inc. must navigate ethical debates around embryo handling and genetic modification, which limit widespread acceptance.
- Limited insurance coverage—Only select states and provinces mandate fertility treatment coverage; Boston Scientific Corporation has advocated for policy expansion, but limited reimbursement remains a barrier.
North America IVF Market Share (%) by Type, 2025
Conventional IVF leads the North America IVF market segment, accounting for nearly half the total market share. IVF with ICSI and IVF with Donor Eggs follow, reflecting the growing demand for procedures addressing male infertility and donor-assisted conception. The diversification of procedural approaches is enabling better patient-tailored treatments, while innovation in PGD/PGS and donor sperm solutions is further expanding access and optimizing success rates. This distribution indicates both the entrenched position of traditional IVF protocols and the rapid acceptance of advanced, adjunctive technologies.
North America IVF Market Share (%) by Application, 2025
Female infertility remains the dominant application area in North America's IVF market, constituting the majority share as awareness and diagnosis continue to improve. Male infertility treatment has gained significant traction, while genetic disorder and embryonic disorder management further expand applications, reflecting the growing reliance on IVF for complex reproductive challenges. Surrogacy, though a smaller segment, is witnessing steady growth owing to changing societal attitudes and supportive legal frameworks, indicating further diversification in IVF utilization across the region.
North America IVF Market Revenue (USD Million), 2020-2035
The North America IVF market revenue demonstrates consistent growth, with a progression from 2,800 Million USD in 2020 to an anticipated 7,240 Million USD in 2035. The increasing uptake of advanced fertility solutions, technology-driven improvements in outcomes, and higher patient access are catalyzing market expansion. Yearly gains are fueled by greater acceptance of IVF, improved insurance coverage in select areas, and demographic trends such as delayed parenthood. This sustained growth trajectory positions IVF as a core pillar of reproductive healthcare across North America.
North America IVF Market YOY (%) Growth, 2020-2035
Year over year (YOY) growth for the North American IVF market averages between 5.5–7.8% from 2020 to 2035, peaking around 2026–2028 as new clinics and advanced treatment options proliferate. While growth rates may moderate in the latter half of the forecast period as the market matures, underlying drivers such as improved outcomes, expanded indications, and rising awareness are expected to sustain positive momentum. Fluctuations reflect the pace of technological adoption and policy/regulatory changes at the state or provincial level.
North America IVF Market Share (%) by Country/Region, 2025
The United States dominates the North America IVF market with over 71% share in 2025, driven by higher technology adoption, greater clinic density, and more favorable regulatory and reimbursement environments. Canada is the second-largest market, accounting for 18%, benefiting from recent public funding expansions for fertility treatments. Mexico, while still developing its advanced IVF sector, contributes 11%, with growth opportunities fueled by medical tourism and increasing local expertise.
North America IVF Market Players Share (%), 2025
Market leadership is divided among several prominent players: Vitrolife AB (19%), CooperSurgical Inc. (17%), Cook Medical (13%), and Thermo Fisher Scientific Inc. (12%) hold the largest shares, reflecting their broad portfolios, research, and service reach. Other key contributors, including Merck KGaA and EMD Serono Inc., demonstrate strong regional influence through specialized solutions and partnerships. This competitive dynamic spurs innovation, collaboration, and ongoing consolidation across the IVF value chain. North America IVF Market Buyers Share (%), 2025
Hospitals & Clinics are the leading buyers in the North American IVF sector, with a 49% share, serving as primary sources of integrated fertility and reproductive health services. Fertility Centers represent 35%, mainly focusing on specialized treatments. Cryobanks, research labs, and pharmacies collectively make up 16%, underscoring the growing importance of support services and biobanking solutions in the IVF value chain.
Study Coverage
| Metrics | Details |
|---|
| Years | 2020-2035 |
| Base Year | 2025 |
| Market Size | 4400 |
| Regions | US, Canada, Mexico |
| Segments | By Type, By Application, By Distribution Channels, By Technology, By Organization Size |
| Players | Vitrolife AB, Cook Medical, CooperSurgical Inc., Thermo Fisher Scientific Inc., Merck KGaA, Irvine Scientific, EMD Serono Inc., Genea Biomedx, Progyny Inc., Boston IVF, The Cooper Companies, OvaScience, Virtus Health, Ferring Pharmaceuticals, Boston Scientific Corporation |
Key Recent Developments
- June 2024: CooperSurgical Inc. launched a next-generation automated embryo assessment platform in North America to improve selection accuracy and outcomes.
- July 2024: Progyny Inc. announced a partnership with a major US employer coalition to expand insurance-based fertility benefits.
- August 2024: Vitrolife AB introduced a new culture media optimized for blastocyst viability, targeting clinics in Canada and the US.
- September 2024: Merck KGaA invested $50 Million in expanding its fertility R&D center in Boston for advancements in personalized IVF.
- October 2024: Thermo Fisher Scientific Inc. acquired an AI startup to bolster its data analytics offerings in embryo and genetic screening.
